Last updated: February 15, 2026
Product Identification
The NDC 76431-0110 refers to Ocrevus (ocrelizumab), a monoclonal antibody indicated for treatment of multiple sclerosis (MS), including relapsing forms and primary progressive MS (PPMS). It is marketed primarily by Roche.
Market Size and Demand Dynamics
Multiple Sclerosis (MS) Market:
-
Global MS market valuation was approximately USD 24.5 billion in 2022, expected to reach USD 40 billion by 2030 (Source: Grand View Research).
-
The US constitutes a major portion, with an estimated 1 million diagnosed patients, growing at about 2.5% annually (Source: National Multiple Sclerosis Society).
Ocrevus Market Share:
-
First approved in 2017 for relapsing MS and PPMS.
-
Captures an estimated 35-45% segment of DMTs (disease-modifying therapies) for MS, competing with agents like Rebif, Tecfidera, and Tysabri.
-
In 2022, Roche reported global sales of approximately CHF 4.4 billion (USD 4.8 billion) for Ocrevus, indicating strong uptake in North America, Europe, and select Asian markets.
Pricing and Reimbursement:
-
US list price ranged from USD 65,000 to USD 70,000 per year per patient in 2022 (Source: SSR Health). Some payers negotiated discounts, reducing actual net price.
-
In Europe, prices average EUR 50,000-60,000 annually, with variation based on country.
Pricing Trends and Projections
Historical Price Trends (2017–2022):
-
Price per dose: USD 32,500-35,000.
-
Dosing schedule: Initial infusion at 600 mg, then 600 mg every six months thereafter.
-
Cost per patient per year: Approx USD 65,000-70,000.
Factors Affecting Future Pricing:
-
Patent lifespan: Set to expire in 2028 for key patents, opening opportunities for biosimilars.
-
Biosimilar development: Several biosimilar candidates are under review, with some expected to launch 1-2 years post-patent expiry, potentially reducing price by 20-40%.
-
Market competition: Emerging therapies, including oral agents and oral S1P modulators, may influence demand and pricing.
-
Payer dynamics: Increasing pressure for price reductions and value-based agreements.
Projected Price Trajectory (2023–2030):
| Year |
Estimated US Net Price per Patient |
Key Influences |
| 2023 |
USD 65,000–70,000 |
Market stability, patent protections |
| 2024 |
USD 63,000–68,000 |
Growing biosimilar approvals, negotiated discounts |
| 2025 |
USD 60,000–65,000 |
Entry of biosimilars, payer discounting |
| 2026 |
USD 58,000–63,000 |
Increased biosimilar market share, competitive pricing |
| 2028 |
USD 50,000–55,000 |
Patent expiry, biosimilars launch |
| 2030 |
USD 45,000–50,000 |
Increased biosimilar adoption, market consolidation |
Competitive Landscape
| Drug |
Administration |
Indications |
Approximate 2022 Revenue |
Price Range (USD/year) |
Patent Status |
| Ocrevus |
IV infusion |
MS, PPMS |
USD 4.8 billion |
65,000 – 70,000 |
Expiring 2028 |
| Tecfidera |
Oral |
MS relapsing |
USD 3.2 billion |
50,000 – 55,000 |
Patents expire late 2020s |
| Kesimpta |
Subcutaneous |
Relapsing MS |
USD 600 million |
55,000 – 60,000 |
Patent intact |
| Biosimilars (pending) |
IV |
MS (generics) |
N/A |
40,000–50,000 (estimated) |
Expected 2028+ |
Market Entry of Biosimilars:
-
Biosimilar versions of ocrelizumab are in late clinical development.
-
Expected to enter markets post-2028, with prices decreasing by approximately 30-40% relative to originator.
Regulatory and Policy Impact
-
US FDA and EMA have already approved Ocrevus; biosimilar approval pathways are established.
-
Price negotiations and value-based contracts are increasingly common in managed markets, influencing net prices.
-
US Inflation Reduction Act and Medicaid best price pressures may lower prices further.
Summary of Key Price Drivers
-
Patent expiration in 2028 opens market access for biosimilars, likely decreasing prices.
-
Increasing global adoption of biosimilar versions, especially in Europe and Asia, will contribute to downward pressure.
-
Payer negotiations and value-based pricing models will impact net revenues.
Key Takeaways
-
The current US list price for Ocrevus remains around USD 65,000–70,000 per year.
-
Biosimilar competition expected post-2028 could reduce prices by 30-40%.
-
The overall MS market is expanding, but pricing pressure will increase as biosimilars mature.
-
Market growth will be driven by patient increase, expanding indications, and drug access policies.
-
Roche remains the dominant supplier; biosimilar entrants will reshape the landscape within the next five years.
FAQs
-
When does the patent for Ocrevus expire, and when will biosimilars likely enter the market?
Patent expiration is expected in 2028, with biosimilars beginning to launch shortly after.
-
How might biosimilar entry affect Ocrevus’s market share and pricing?
Biosimilars will likely capture a significant portion of the market, leading to a 30-40% reduction in prices of the originator.
-
What are the main factors influencing future drug prices?
Patent expirations, biosimilar development, payer negotiations, and policy changes.
-
How does Ocrevus compare to other MS therapies in price and market share?
It is among the most expensive MS treatments at USD 65,000–70,000/year, with a 35-45% market share as of 2022.
-
What are the risks to Roche’s revenue from Ocrevus?
Patent expiry, biosimilar competition, and increased price negotiations pose risks. Market expansion depends on adoption in emerging markets and indications.
References
- Grand View Research. Multiple Sclerosis Market Size, Trends & Forecasts. 2022.
- National Multiple Sclerosis Society. MS Prevalence Data. 2022.
- SSR Health. U.S. Drug Pricing and Market Share Data. 2022.
- Roche. Ocrevus Annual Report. 2022.
- European Medicines Agency. Ocrelizumab (Ocrevus) Summary of Product Characteristics. 2022.
- FDA. Biosimilar and Interchangeable Products Data. 2022.
